Diagnostic Radiopharmaceuticals
for TheranosticsPETNET Solutions provides essential PET diagnostic radiopharmaceuticals for effective theranostics
Theranostics begins with diagnostics
PETNET Solutions can help you maintain PET/CT imaging continuity with a vast distribution network providing the efficient delivery of PET radiopharmaceuticals necessary for the diagnostic phase of theranostics.
Patient selection
Pre-therapy PET 18F-PSMA
Appropriate patient selection is key to optimizing patient outcomes. For example, the use of PSMA-targeted therapy will only be effective against tumor lesions with sufficient expression of the target receptor.
Emerging data has shown the superiority of PSMA imaging with PET/CT over conventional imaging for primary diagnoses. Single photon emission computed tomography (SPECT) is more available worldwide, and the imaging agent is low in cost.1 The pattern of tumor PSMA expression should be evaluated per molecular imaging (preferred: 68Ga/18F-PSMA PET; alternatively: 99mTc-PSMA SPECT)2
In this case, a comprehensive evaluation of initial metastatic burden a pre-therapy 18F-PSMA PET scan displayed significant burden of PSMA-avid abdominopelvic and mediastinal nodal metastases.
Data courtesy of University Hospital Heidelberg, Heidelberg, Germany.
177Lu-PSMA therapy
Once the extent of disease has been confirmed 177Lu-PSMA therapy was given with post therapy planar imaging following each cycle.
Post-therapy imaging
18F-PSMA PET performed 1 year following therapy shows complete response to therapy with absence of PSMA-avid disease
Education opportunity
Theranostics is rapidly growing due to its ability to offer personalized medicine, enabling more precise targeting of treatments based on a patient's specific disease. Advances in imaging technologies have fueled this growth, improving the accuracy of diagnoses and effectiveness of treatments.
Join Lady Sawoszczyk, BS, CNMT, Global Lead for Theranostics Solutions at Siemens Healthineers, for an insightful session on establishing and optimizing a theranostic program. Drawing from her extensive experience, Lady provides consulting services to healthcare institutions, guiding them through the development and enhancement of their theranostics programs. Previously, at a large academic medical center in New York City, she developed a comprehensive theranostics program encompassing imaging, clinical trials, radiopharmaceutical manufacturing, and patient management software.
Watch the webinar now: Establishing a theranostics program
Current PETNET Solutions customers can access 23 on-demand educational webinars with free VOICE CEC on MI PET Source.
Discover resources from PETNET to help support your theranostics program
More information
Theranostics for personalized cancer care
Using molecular imaging to identify specific biomarkers, theranostics allows targeted treatment tailored to individual patients, improving efficacy and minimizing side effects. This integrated approach enhances precision in diagnosing diseases like cancer and delivering therapies directly to affected tissues, revolutionizing patient care.
Discover how theranostics is transforming personalized medicine.
Contact us
PETNET Solutions customer care team
email: customercare@petnetsolutions.com
phone: (877)-473-8643
PETNET Solutions Corporate Office
810 Innovation Drive
Knoxville, TN 37932 USA
